Clinical protocols, member stories, and plain-language science from the Meto care team. We publish what we'd want to read if we were figuring this out for the first time
Six next generation GLP-1 drugs are advancing through the FDA pipeline in 2026, each targeting weight loss and metabolic health through novel mechanisms beyond semaglutide.
